Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows provided by (used in) operating activities:
Net earnings (loss)	$ 77.0	$ (2.7)
Adjustments to reconcile net earnings to cash provided by operating activities:
Depreciation and amortization	499.2	188.6
Share-based compensation	30.7	21.2
Non-cash Biomet merger consideration compensation expense		164.1
Intangible asset impairment	28.0
Excess income tax benefit from stock option exercises		(9.1)
Inventory step-up	286.4	10.5
Loss on divestiture of assets		3.4
Changes in operating assets and liabilities, net of effect of acquisitions:
Income taxes	13.6	95.9
Receivables	(120.8)	(59.3)
Inventories	60.2	(140.8)
Accounts payable and accrued expenses	(141.9)	102.4
Other assets and liabilities	(80.0)	(85.5)
Net cash provided by operating activities	652.4	288.7
Cash flows provided by (used in) investing activities:
Additions to instruments	(157.3)	(104.0)
Additions to other property, plant and equipment	(73.7)	(64.8)
Purchases of investments	(1.2)	(152.6)
Sales of investments	273.3	398.9
Proceeds from divestiture of assets		24.1
Biomet acquisition, net of acquired cash		(7,812.9)
Other business combination investments, net of acquired cash	(184.1)
Investments in other assets	(27.4)	(9.4)
Net cash used in investing activities	(170.4)	(7,720.7)
Cash flows provided by (used in) financing activities:
Proceeds from senior notes		7,628.2
Proceeds from term loan		3,000.0
Redemption of senior notes		(2,740.0)
Payments on term loan	(500.0)
Net proceeds (payments on) under revolving credit facilities	(18.8)	0.9
Dividends paid to stockholders	(92.4)	(74.7)
Proceeds from employee stock compensation plans	78.6	34.6
Excess income tax benefit from stock option exercises		9.1
Restricted stock witholdings	(5.2)	(10.4)
Debt issuance costs		(58.4)
Repurchase of common stock	(415.5)
Net cash (used in) provided by financing activities	(953.3)	7,789.3
Effect of exchange rates on cash and cash equivalents	(11.7)	(16.0)
(Decrease) increase in cash and cash equivalents	(483.0)	341.3
Cash and cash equivalents, beginning of year	1,459.3	1,083.3
Cash and cash equivalents, end of period	$ 976.3	$ 1,424.6